abstract |
A novel anti-CD25 monoclonal antibody (daclizumab) with improved properties is provided. It is adapted to grow in serum-free and cholesterol-free media and can achieve volumetric productivity in excess of 100 mg / L / day recombinant protein in 100 L culture in a 10-day fed-batch process. Modified NS0 cells, and methods for producing daclizumab with reduced ADCC cytotoxicity and compositions suitable for subcutaneous administration using the modified NS0 cells. [Selection figure] None |